Gmax Starts China Phase I Trial of 2nd Gen Obesity Therapy
November 11, 2021 at 05:09 AM EST
Gmax Biopharm, a novel Hangzhou antibody company focused on GPCRs, has begun a China Phase I trial of its obesity therapy. GMA106 is Gmax's second-gen mAb therapy aimed at obesity/T2DM/NASH. It combines Gmax's GPCR mAb with its M-Body technology, which aims at two different targets for better efficacy. In this case the M-Body pairs an anti-GIPR antibody fused with a GLP-1 peptide. Patients in the Phase I trial will be given a single dose of GMA106. The trial will be structured as a placebo controlled, double blind, randomized, dose escalating study. More details.... Share this with colleagues: // //